Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acolbifene - Endoceutics

Drug Profile

Acolbifene - Endoceutics

Alternative Names: Acolbifene hydrochloride; EM 652.HCl; EM-652; SCH 57068; SCH 57068.HCl

Latest Information Update: 11 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endoceutics
  • Developer Endoceutics; National Cancer Institute (USA)
  • Class Antineoplastics; Benzopyrans; Osteoporosis therapies; Phenyl ethers; Piperidines
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 11 Jul 2019 Phase III development for Breast cancer is ongoing in Canada (Endoceutics pipeline, July 2019)
  • 24 Jun 2018 Biomarkers information updated
  • 09 Oct 2015 No recent reports on development identified - Phase-II for Breast cancer (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top